The small leucine-rich proteoglycan BGN accumulates in CADASIL and binds to NOTCH3

Xiaojie Zhang1, Soo Jung Lee, Marian F Young

  • 1Department of Neurology, University of Michigan, 7725 Medical Science Building II Box 5622, 1137 Catherine St., Ann Arbor, MI, 48109-5622, USA.

Insights

Biglycan (BGN) accumulates in cerebral arteries in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL). This accumulation is linked to NOTCH3 protein interactions and mTOR pathway activation, offering new insights into CADASIL pathogenesis.

Area of Science:

  • Neurology
  • Vascular Biology
  • Genetics

Background:

  • Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) is an inherited cerebral small vessel disease.
  • NOTCH3 mutations cause CADASIL, leading to arterial fibrosis and NOTCH3 accumulation.
  • Small leucine-rich proteoglycans (SLRPs) like biglycan (BGN) regulate collagen and may be involved in CADASIL.

Purpose of the Study:

  • To investigate the accumulation of biglycan (BGN) in the arteries of CADASIL brains.
  • To explore the relationship between BGN, NOTCH3, and the mTOR pathway in CADASIL.

Main Methods:

  • Immunohistochemistry and immunoblotting to detect BGN protein levels and localization in CADASIL and control brains.
  • In situ hybridization to assess BGN mRNA expression.
  • In vitro studies using human cerebrovascular smooth muscle cells exposed to NOTCH3 ectodomain.
  • Protein-protein interaction assays.

Main Results:

  • BGN protein and mRNA were significantly increased in the arteries of CADASIL brains compared to controls.
  • BGN localized to all three layers of CADASIL arteries.
  • NOTCH3 ectodomain exposure upregulated BGN, decorin (DCN), and collagen type IV alpha 1 chain (COL4A1) in smooth muscle cells via an mTOR-sensitive pathway.
  • BGN directly interacted with NOTCH3 protein.

Conclusions:

  • Biglycan (BGN) is a key protein that accumulates in cerebral vessels in CADASIL.
  • BGN accumulation may be driven by mTOR-mediated transcriptional upregulation and/or post-translational interactions with NOTCH3.
  • These findings highlight BGN as a potential therapeutic target for CADASIL.